Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Four year follow up of CheckMate 238 demonstrated sustained recurrence-free survival benefit with nivolumab versus ipilimumab (n=906; 51.7% vs 41.2%; HR 0.71 [95% CI 0.60–0.86]; p=0.0003) and similar 4-year overall survival (77.9% vs 76.6%; HR 0.87 [95% CI 0·66–1.14]; p=0.31).


The Lancet Oncology